 In 2017 by Bristol-Myers partnered one of the Adnexus programs to Roche, an anti-myotstatin program that has completed phase-2 testing in Duchenne patients.After Adnexus, Mendlein helped found Fate Therapeutics (), a cell-based therapy company, in San Diego, and became its chairman.He served on the board of directors of Monogram Biosciences, Inc., an HIV and oncology diagnostic company that was acquired by Laboratory Corporation of America Holdings in 2009.